Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer Institute.
Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer Institute.
复制标题
从人类实体瘤制备活肿瘤细胞疫苗:肿瘤质量与细胞产量之间的关系。
DOI:
10.1097/00008390-199311000-00008
复制
发表时间:
1993
影响因子:
2.2
通讯作者:
Straw,LD
中科院分区:
文献类型:
--
作者:
Logan,TF;Shannon,W;Bryant,J;Kane,P;Wolmark,N;Posner,M;Kirkwood,JM;Ernstoff,MS;Futrell,JW;Straw,LD
Active specific Immunotherapy for cancer often requires the use of autologous or allogeneic tumour cells as Immunizing antigen. Tumours were obtained for such a protocol. However, estimation of viable cell yield from pre-processed fresh tumour mass was difficult, and Initially there did not appear to be a direct relationship between pre-processed tumour mass and viable cells obtained after processing. We therefore analysed all of 293 tumour specimens processed to attempt to discern such a relationship. Of these 137 were melanoma, 14 were sarcoma, 48 were adenocarcinoma, 59 were renal cell carcinoma and 35 were classified as other. A positive correlation was found between pre-processed tumour mass and viable cell yield, with Spearman correlation values varying from r= 0.49 (adenocarcinoma) to r= 0.84 (melanoma). For all tumours the Spearman correlation was r= 0.70 (p= 0.0001). Not surprisingly, the most frequent site of removal associated with bacterial contamination was bowel. In conclusion, this study provides useful curves for predicting viable tumour cell yield from pre-processed tumour mass of given histology.